以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 在减重门诊的候诊区，阿慧第一次见到这么多和她一样为体重苦恼的人。从体重指数高达39kg/m²的50岁阿姨，到自嘲"喝水也长胖"的年轻小 哥，每个人背后都有自己的故事和压力。 《中国居民营养与慢性病状况报告（2020年）》数据显示，2018年我国18岁及以上人群超重率为34.3%，肥胖率为16.4%，成年肥胖症患者已 高达1.82亿。然而，现实中"肥胖"往往被误解为"生活习惯不自律"或"缺乏意志力"，这种认知误区和偏见让许多患者在求医路上倍感艰难。 其实，并非所有超重者都需医学干预，但肥胖症作为一种内分泌代谢疾病，确实属于疾病体系范畴。复旦大学附属中山医院内分泌科主任李小 英指出，肥胖症如果不及时系统干预，相关健康风险将持续累积并加重。近年来，政策层面也在加快响应。 2025年4月，国家卫生健康委与国家中医药局联合发文，鼓励有条件的三级综合医院、儿童医院及中医医院开设健康体重管理门诊。要求到 2025年6月底，相关医院基本实现体重管理门诊全覆盖。5月11 ...

STEP 5 是一项 3b 期随机、双盲、安慰剂对照试验，研究了 2.4 毫克司美格鲁肽作为生活方式干预（每日 500 千卡饮食加上每周 150 分钟体力 活动）的辅助手段对 304 名肥胖且无 2 型糖尿病的成年人持续减重（2 年）的影响。参与者被随机分配（以 1:1 的比例）每周一次皮下注射 2.4 毫克司美格鲁肽或安慰剂，持续 104 周。 试验的主要终点是体重变化（%）和第104 周体重减轻≥5% 的参与者比例。关键次要目标包括第104 周体重较基线减少≥10% 或≥15% 的参与者 比例，以及腰围和收缩压从基线到第 104 周的变化。 整理 | GLP1减重宝典内容团队 STEP 5中为STEP系列研究中观察时间最长的，为期108周，该研究表明司美格鲁肽2.4mg可以用于长期体重管理。 STEP（司美格鲁肽对肥胖患者的治疗效果）是一项 3 期临床开发计划，每周一次皮下注射 2.4 毫克司美格鲁肽治疗肥胖症。全球临床 3a 期计 划包括四项试验，招募了约 4,500 名超重或肥胖的成年人。在 STEP 试验中，主要估计对象（治疗政策估计对象）评估效果，无论是否坚持治 疗或是否开始其他抗肥胖疗法。次要估 ...

Group 1 - The core achievement of Hangzhou Xianweida Biotechnology Co., Ltd. is the successful Phase III clinical trial results of the world's first "biased" weight loss drug, Enoglutide, presented at the American Diabetes Association annual meeting and published in The Lancet Diabetes & Endocrinology [1][2] - The drug demonstrated significant efficacy, with patients in the highest dosage group (2.4mg) losing an average of 15.1% of their body weight over 48 weeks, equating to a 10 kg loss for a 70 kg individual [3] - 92.8% of patients achieved a weight loss of over 5%, a recognized medical standard for effective weight loss, compared to only 13.9% in the placebo group [3] Group 2 - The Chinese government has designated 2025 as the "Year of Weight Management," highlighting the increasing focus on obesity issues and the potential for pharmaceutical interventions [1] - Goldman Sachs predicts that the global anti-obesity drug market could reach $100 billion by 2030, indicating a significant growth opportunity in this sector [1] - Xianweida is one of the earliest companies to focus on the biased GLP-1 design concept, differentiating itself from competitors like Novo Nordisk and Eli Lilly, which primarily develop conventional GLP-1 drugs [2] Group 3 - The company has received substantial support from the Qiantang District, which has fostered a conducive environment for biopharmaceutical development, including financial backing and talent acquisition [4] - Xianweida has undergone seven rounds of financing, with cumulative investments in product development nearing 1 billion yuan, demonstrating strong financial backing [4] - Enoglutide is expected to enter the market by early 2026, potentially becoming another innovative product from Qiantang following the recent launch of another innovative drug [4]

市场消息：在《新英格兰医学杂志》发表的完整iii期研究结果显示，礼来(LLY.N)的口服肥胖症药物 Orforglipron显示出令人信服的疗效和安全性，与注射GLP-1药物一致。 ...

Core Insights - Novo Nordisk's new injectable obesity drug, amycretin, shows significant weight loss potential, outperforming current market leaders [1][4] - In early trials, participants receiving the highest dose of amycretin lost an average of 24.3%, compared to 1.1% in the placebo group, surpassing Eli Lilly's Zepbound (22.5%) and Novo's own Wegovy (15%) [1][4] - The company is under pressure to demonstrate its drug pipeline can compete effectively against Eli Lilly, especially after a nearly 50% drop in stock price over the past year [1] Drug Development and Efficacy - Amycretin combines the active ingredients of Wegovy and Ozempic with the hormone incretin to enhance satiety [4] - An oral version of amycretin also showed promise, with participants in the highest dose group losing an average of 13.1%, compared to 1.2% in the placebo group [4] - The absence of a plateau in weight loss during the 12-week trial suggests potential for greater weight loss in longer trials or real-world applications [4] Competitive Landscape - The positive results for amycretin are crucial for Novo Nordisk, especially following disappointing results from another obesity drug, CagriSema, which led to a significant stock price drop [5] - Analysts remain optimistic about Eli Lilly's oral obesity drug, orforglipron, which achieved an average weight loss of 14.7% in a 36-week phase 2 study [5] - Novo Nordisk has submitted an approval application for the oral version of Wegovy, based on trial data showing an average weight loss of 16.6% over 64 weeks [5]

这项研究强调了嗅觉在食欲调节和肥胖发展中的重要作用。新发现表明，食物的气味在日常饮食习惯中 扮演了关键角色。更重要的是，这条神经通路只在体重正常的小鼠中能降低食欲，而在肥胖小鼠中失 效，这为预防肥胖小鼠暴饮暴食开辟了一条新途径。 美食当前，有人却说"闻着都感觉饱了"？据《自然·代谢》杂志11日报道，德国马克斯·普朗克代谢研究 所团队通过动物实验发现，一种新的神经细胞网络是造成这一现象的原因。这也揭示了嗅觉是如何影响 进食行为的，为肥胖症的预防和治疗提供了全新思路。 团队通过脑部扫描技术，在小鼠大脑的内侧隔膜中发现了一组新的神经细胞。当小鼠闻到食物气味时， 这些神经细胞会被激活，并产生饱腹感。由于这些神经细胞与负责嗅觉的嗅球直接相连，因此这个过程 会在几秒钟内完成。这些神经细胞很"馋"，对多种食物气味敏感，却不会对其他无关气味作出反应。 有趣的是，当小鼠开始进食后，这些神经细胞的活性会被抑制，这保证了正常的饮食过程。这些神经细 胞如果活跃，则会有效缩短进食时间，有助于野外小鼠减少被捕食的风险。 然而，在肥胖小鼠身上，这种神经细胞对食物气味的反应明显减弱甚至缺失，导致它们闻到食物香味时 并不会感到饱，进食量也没有 ...

Metsera, Inc. MTSR on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability with Metsera’s fully-biased monthly GLP-1 receptor agonist candidate, MET-097i.In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile with no safety signals.MET-233i was evaluate ...

整理 | GLP1减重宝典内容团队 替尔泊肽是一种新型的每周一次的 GIP（葡萄糖依赖性胰岛素促泌多肽）受体和 GLP-1（胰高血糖素样肽-1）受体激动剂，代表了一类正在研 究的治疗肥胖症的药物。替尔泊肽是一种激活人体 GIP 和 GLP-1 受体（两种天然肠促胰岛素激素）的单肽。 肥胖症是一种慢性进行性疾病，由控制体重的机制中断引起，通常导致食物摄入量增加和/或能量消耗减少。这些中断是多因素的，可能与遗 传、发育、行为、环境和社会因素有关。 ▍个体差异显著：替尔泊肽并非人人适用 在SURMOUNT-1试验中，研究招募了 2,539 名参与者，参与者的平均基线体重为105 公斤。 试验结果平均体重减轻：16.0%（5 毫克时16 公斤）、21.4%（10 毫克时22 公斤）和 22.5%（15 毫克时24 公斤），而安慰剂组（2.4%或 2 公 斤）。 然而要达到这样的效果，试验引入了低热量饮食和增加身体活动的辅助手段 ，所以要达到这样的效果需搭配生活方式改变。 89%（5 毫克）和 96%（10 毫克和 15 毫克）的人体重减轻了至少 5%，而服用安慰剂的人中，这一比例仅为 28%。 所以替尔泊肽对有的人可 ...

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 "不是所有体重超标的人都需要医学干预，但肥胖症确实属于疾病范畴。"复旦大学附属中山医院内分泌科主任李小英表示，肥胖症是一种内分 泌和代谢性疾病，如果不及时系统干预，相关健康风险会逐步累积甚至恶化。政策层面的响应也在不断加快。2025年4月，国家卫生健康委联 合国家中医药局下发通知，鼓励有条件的三级综合医院、儿童医院和中医医院开设健康体重管理门诊。要求国家卫生健康委、国家中医药局直 属和地方各级综合医院、儿童医院、中医医院，在2025年6月底前基本实现体重管理门诊的全覆盖。 5月11日，正值"世界防治肥胖日"，曾被视为个人隐私的体重问题，如今已成为公众热议的焦点。其背后，不仅有肥胖率持续上升的健康隐忧， 更有GLP-1受体激动剂（GLP-1RA）等新型减重药物的出现，让越来越多人意识到：减重，已经不再只是个人选择，而是需要医学介入的重要 健康课题。 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 在减重门诊的候诊区，阿慧第一次见到了这么多和自己一样为体重苦恼的"同路人"。从BMI高达39kg/m²的5 ...

Core Viewpoint - The release of the "Health Weight Management Center Construction Management Specification" marks a significant step in standardizing the construction and management of health weight management centers in China, addressing the growing obesity issue through a structured approach [1][2] Group 1: Background and Importance - China's obesity problem has become increasingly severe, necessitating the establishment of health weight management centers as a new medical model based on evidence-based medicine [1] - The specification provides a replicable and promotable template for obesity prevention and treatment, filling a gap in the domestic obesity prevention and treatment system [1][2] Group 2: Key Features of the Specification - The specification outlines requirements for functional layout, personnel configuration, diagnostic processes, and quality control, ensuring a comprehensive approach to weight management [1] - It introduces the internationally recognized "5A" service model for patient management, which includes initial screening, clinical decision-making, execution, and follow-up [2] - The specification defines the organizational structure, application processes, regulations, and personnel training management for standardized weight management centers [2] Group 3: Implementation and Future Plans - A nationwide tour of interpretative sessions is planned to promote the specification's normative, innovative, and forward-looking aspects, with over 20 offline meetings scheduled from June to December in key provinces and cities [2] - The establishment of health weight management centers is expected to become a crucial front in obesity prevention and control, providing evidence-based methods and scientific procedures for clinical practice [2]